Genzyme takes up option on Alnylam's ALN-AT3 hemophilia program

1 October 2015

Genzyme, the USA-based biotech subsidiary of French pharma major Sanofi (Euronext: SAN), has elected to opt into Alnylam Pharmaceutical's (Nasdaq: ALNY) investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.

This marks the first product from Alnylam's Genetic Medicines pipeline to which Genzyme has opted in since the formation of the companies' global alliance last year (The Pharma Letter January 13, 2014), and the third product opt-in overall. Genzyme's opt-in decision was based on encouraging clinical data from the Phase I trial of ALN-AT3, including positive interim data that were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in June 2015.

Terms of the agreement

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK